GH Research (GHRS) Reports Q3 Net Loss of $1.8M, Cash Position of $280.7M, Issues Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 5/20/2022
- Wall Street ends lower as Cisco and Apple sink
- A Recession Could Push S&P 500 to 3360 - Goldman Sachs
- Palo Alto Networks Shares Surge 11% on Q3 Earnings Beat and Raise
- Twitter (TWTR) Says Musk Deal Not 'On-Hold', Won't Renegotiate Price
- After-Hours Stock Movers 05/19: Palo Alto Ramps on Strong Results; Ross Stores Plunges (more...)
- A Recession Could Push S&P 500 to 3360 - Goldman Sachs
- 'Epic Disaster': Tech Bull Daniel Ives Cuts Tesla (TSLA) Stock Price Target by $400 on 'Hard to Ignore' China Lockdowns
- Wall Street ends lower as Cisco and Apple sink
- Magnachip Semiconductor (MX) Offer in Mid-$20s or Above Could Get Deal Done - Oppenheimer
- Deckers Brands (DECK) Announces Resignation of President of Performance Lifestyle
- After-Hours Stock Movers 05/19: Palo Alto Ramps on Strong Results; Ross Stores Plunges (more...)
- Companies with NDRs 5/19
- After-Hours Stock Movers 05/18: Cisco Plunges on Weak Results and Outlook; Synopsys Jumps on Results (more...)
- Pre-Open Stock Movers 05/18: Target Plunges on Weak Results, Outlook; National CineMedia Gains on AMC Stake
- Companies with NDRs 5/18
GH Research (GHRS) Reports Successful Outcome of the Phase 2 part of its Phase 1/2 Clinical Trial of GH001
December 6, 2021 7:00 AM ESTGH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported the successful outcome of the Phase 2 part of a Phase 1/2 clinical trial of GH001, an inhalable 5-MeO-DMT product candidate, in patients with treatment-resistant... More
